9:41
●●● 5G
Which patient are you considering Imfinzi for?
Unresectable Stage III NSCLC
Based on PACIFIC — the curative-intent standard of care for patients whose disease has not progressed after concurrent chemoradiotherapy (CRT).
- Long-term overall survival benefit in the PACIFIC trial
- Start consolidation within 42 days of completing CRT
- Dosing: 10 mg/kg q2w or 1500 mg q4w
Resectable NSCLC (neoadjuvant + adjuvant)
Based on AEGEAN — perioperative durvalumab: neoadjuvant with platinum chemo, then adjuvant durvalumab after surgery, for resectable tumors ≥4 cm and/or node-positive.
- Event-free survival benefit vs. chemo alone
- Neoadjuvant + adjuvant regimen
- For resectable ≥4 cm and/or node-positive NSCLC
Limited-stage SCLC
Based on ADRIATIC — durvalumab for patients whose disease has not progressed following concurrent platinum-based chemoradiation.
- Significant overall survival benefit in ADRIATIC
- For LS-SCLC after concurrent platinum CRT
- First immunotherapy approved in this setting
Bladder cancer (MIBC or high-risk NMIBC)
Two pathways: NIAGARA (perioperative durvalumab with gem/cis for muscle-invasive bladder cancer) and POTOMAC (durvalumab + BCG for BCG-naïve high-risk NMIBC).
- MIBC: neoadjuvant gem/cis + durvalumab, then adjuvant (NIAGARA)
- High-risk NMIBC: durvalumab + BCG (POTOMAC, approved 2026)
- Select the setting that matches your patient
Another tumor type
Imfinzi is also approved across several GI and gynecologic settings. Tell us the tumor type and we'll route you to the right data.
- Resectable gastric/GEJ adenocarcinoma with FLOT (MATTERHORN)
- Biliary tract cancer with gem/cis (TOPAZ-1); HCC with tremelimumab (HIMALAYA)
- dMMR primary advanced/recurrent endometrial cancer
